These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18831929)

  • 1. Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential.
    Barbisan F; Mazzucchelli R; Santinelli A; Stramazzotti D; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
    Int J Immunopathol Pharmacol; 2008; 21(3):615-23. PubMed ID: 18831929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis.
    Mazzucchelli R; Scarpelli M; Lopez-Beltran A; Cheng L; Bartels H; Bartels PH; Alberts DS; Montironi R
    Int J Immunopathol Pharmacol; 2011; 24(2):489-97. PubMed ID: 21658323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
    Barbisan F; Santinelli A; Mazzucchelli R; Lopez-Beltran A; Cheng L; Scarpelli M; van der Kwast T; Montironi R
    Cancer; 2008 Feb; 112(3):636-44. PubMed ID: 18072261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromatin phenotype karyometry can predict recurrence in papillary urothelial neoplasms of low malignant potential.
    Montironi R; Scarpelli M; Lopez-Beltran A; Mazzucchelli R; Alberts D; Ranger-Moore J; Bartels HG; Hamilton PW; Einspahr J; Bartels PH
    Cell Oncol; 2007; 29(1):47-58. PubMed ID: 17429141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections.
    Castellini P; Montironi MA; Zizzi A; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Paone N; Montironi R
    Hum Pathol; 2014 Apr; 45(4):745-52. PubMed ID: 24565208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma.
    Zizzi A; Montironi MA; Mazzucchelli R; Scarpelli M; Lopez-Beltran A; Cheng L; Paone N; Castellini P; Montironi R
    Diagn Pathol; 2013 Jul; 8():111. PubMed ID: 23819605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Karyometry detects subvisual differences in chromatin organisation state between non-recurrent and recurrent papillary urothelial neoplasms of low malignant potential.
    Scarpelli M; Montironi R; Tarquini LM; Hamilton PW; López Beltran A; Ranger-Moore J; Bartels PH
    J Clin Pathol; 2004 Nov; 57(11):1201-7. PubMed ID: 15509685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.
    Maxwell JP; Wang C; Wiebe N; Yilmaz A; Trpkov K
    Diagn Pathol; 2015 Mar; 10():3. PubMed ID: 25886613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
    Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
    Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced 5-methylcytosine level as a potential progression predictor in patients with T1 or non-invasive urothelial carcinoma.
    Chung CJ; Chang CH; Chuu CP; Yang CR; Chang YH; Huang CP; Chen WC; Chung MC; Chang H
    Int J Mol Sci; 2014 Dec; 16(1):677-90. PubMed ID: 25561224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of MUC1 (Ma695) in noninvasive papillary urothelial neoplasm according to the 2004 World Health Organization classification of the noninvasive urothelial neoplasm. An immunologic tool for the pathologist?
    Garbar C; Mascaux C
    Anal Quant Cytol Histol; 2011 Oct; 33(5):277-82. PubMed ID: 22611755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reappraisal of the papillary urothelial neoplasm of low malignant potential (PUNLMP).
    Jones TD; Cheng L
    Histopathology; 2020 Oct; 77(4):525-535. PubMed ID: 32562556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma.
    Park YS; Jin MY; Kim YJ; Yook JH; Kim BS; Jang SJ
    Ann Surg Oncol; 2008 Jul; 15(7):1968-76. PubMed ID: 18470569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do DNA-methylation and histone acetylation play a role in clear cell renal carcinoma? Analysis of radical nephrectomy specimens in a long-term follow-up.
    Minardi D; Lucarini G; Filosa A; Zizzi A; Milanese G; Polito M; Polito M; Di Primio R; Montironi R; Muzzonigro G
    Int J Immunopathol Pharmacol; 2011; 24(1):149-58. PubMed ID: 21496397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global histone modification patterns predict risk of prostate cancer recurrence.
    Seligson DB; Horvath S; Shi T; Yu H; Tze S; Grunstein M; Kurdistani SK
    Nature; 2005 Jun; 435(7046):1262-6. PubMed ID: 15988529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global and specific histone acetylation pattern in patients with Balkan endemic nephropathy, a worldwide disease.
    Kocic G; Cukuranovic J; Stoimenov TJ; Cukuranovic R; Djordjevic V; Bogdanovic D; Stefanovic V
    Ren Fail; 2014 Aug; 36(7):1078-82. PubMed ID: 24845033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder papillary urothelial neoplasm of low malignant potential in Chinese: a clinical and pathological analysis.
    Zhang XK; Wang YY; Chen JW; Qin T
    Int J Clin Exp Pathol; 2015; 8(5):5549-55. PubMed ID: 26191263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.
    Lin X; Zhu B; Villa C; Zhong M; Kundu S; Rohan SM; Yang XJ
    Hum Pathol; 2014 Sep; 45(9):1824-9. PubMed ID: 24993315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma.
    Mai KT; Busca A; Belanger EC
    Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subvisual changes in chromatin organization state are detected by karyometry in the histologically normal urothelium in patients with synchronous papillary carcinoma.
    Montironi R; Scarpelli M; Mazzucchelli R; Hamilton PW; Thompson D; Ranger-Moore J; Bostwick DG; Bartels PH
    Hum Pathol; 2003 Sep; 34(9):893-901. PubMed ID: 14562285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.